Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Relapse Prevention in Mandibular Advancement
NCT05573581Phase 3Unknown
- Sponsor
- Cairo University
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial in mandibular retrognathism comparing Botox injection group with placebo group (2 arms). Primary endpoint: Skeletal Relapse at 6 months. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
mandibular retrognathism
Beyond the preview
Go deeper on NCT05573581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05573581.